Modified IPCW model: A method for adjusting for bias in the estimation of overall survival due to the use of second and third line therapies in locally advanced or metastatic pancreatic cancer patients.

Escobar, N. E. IznagaLuaces, Patricia LorenzoValdes, Lizet SanchezSilva, Carmen ValenzuelaRamos, Tania CrombetStrumberg, DirkSchultheis, BeateEbert, Matthias PhilipKerkhoff, AndreaHofheinz, RalfBehringer, Dirk M.Schmidt, Wolfgang E.Goker, ErdemDe Doss, SaraKneba, MichaelYalcin, SuayibOverkamp, FriedrichSchlegel, FrankMarkus2019-10-272019-10-2720170732-183X1527-7755https://doi.org/10.1200/JCO.2017.35.15_suppl.e15787https://hdl.handle.net/11454/3211453rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET -- JUN 02-07, 2017 -- Chicago, ILen10.1200/JCO.2017.35.15_suppl.e15787info:eu-repo/semantics/closedAccessModified IPCW model: A method for adjusting for bias in the estimation of overall survival due to the use of second and third line therapies in locally advanced or metastatic pancreatic cancer patients.Conference Object35WOS:000411931701173Q1